Achieve Life Sciences Inc (SP4P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has a cash flow conversion efficiency ratio of -0.649x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.93 Million ≈ $-8.10 Million USD) by net assets (€10.68 Million ≈ $12.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SP4P market cap for the company's overall valuation and market capitalisation.
Achieve Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Achieve Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Achieve Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Achieve Life Sciences Inc ranked by their cash flow conversion efficiency. See debt repayment capacity of Achieve Life Sciences Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wheels India Limited
NSE:WHEELS
|
0.411x |
|
Franklin BSP Realty Trust Inc
NYSE:FBRT
|
-0.036x |
|
Guangxi Nanning Waterworks Co
SHG:601368
|
0.039x |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
0.103x |
|
SeaBird Exploration Plc
OL:SBX
|
0.148x |
|
Konka Group Co Ltd
SHE:000016
|
0.068x |
|
Anhui Huamao Textile Co Ltd
SHE:000850
|
0.117x |
|
ShenZhen Zero-Seven Co Ltd
SHE:000007
|
0.554x |
Annual Cash Flow Conversion Efficiency for Achieve Life Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Achieve Life Sciences Inc from 2016 to 2025. View latest Achieve Life Sciences Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €21.52 Million ≈ $25.16 Million |
€-49.47 Million ≈ $-57.83 Million |
-2.299x | -61.38% |
| 2024-12-31 | €20.90 Million ≈ $24.43 Million |
€-29.77 Million ≈ $-34.80 Million |
-1.424x | -108.43% |
| 2023-12-31 | €-1.45 Million ≈ $-1.69 Million |
€-24.48 Million ≈ $-28.62 Million |
16.905x | +473.82% |
| 2022-12-31 | €8.30 Million ≈ $9.71 Million |
€-37.55 Million ≈ $-43.90 Million |
-4.522x | -330.76% |
| 2021-12-31 | €28.04 Million ≈ $32.78 Million |
€-29.44 Million ≈ $-34.42 Million |
-1.050x | -190.52% |
| 2020-12-31 | €37.29 Million ≈ $43.59 Million |
€-13.47 Million ≈ $-15.75 Million |
-0.361x | +57.13% |
| 2019-12-31 | €18.05 Million ≈ $21.10 Million |
€-15.22 Million ≈ $-17.79 Million |
-0.843x | -25.40% |
| 2018-12-31 | €15.80 Million ≈ $18.47 Million |
€-10.62 Million ≈ $-12.42 Million |
-0.672x | +41.84% |
| 2017-12-31 | €7.88 Million ≈ $9.21 Million |
€-9.11 Million ≈ $-10.65 Million |
-1.156x | -10752.47% |
| 2016-12-31 | €18.97 Million ≈ $22.17 Million |
€-202.00K ≈ $-236.16K |
-0.011x | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more